[go: up one dir, main page]

WO2016100349A3 - Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists - Google Patents

Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists Download PDF

Info

Publication number
WO2016100349A3
WO2016100349A3 PCT/US2015/065829 US2015065829W WO2016100349A3 WO 2016100349 A3 WO2016100349 A3 WO 2016100349A3 US 2015065829 W US2015065829 W US 2015065829W WO 2016100349 A3 WO2016100349 A3 WO 2016100349A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor antagonists
nmda receptor
nr2b
formula
azaheterocyclic compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/065829
Other languages
French (fr)
Other versions
WO2016100349A2 (en
Inventor
Gideon Shapiro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rugen Holdings (cayman) Ltd
Original Assignee
Rugen Holdings (cayman) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rugen Holdings (cayman) Ltd filed Critical Rugen Holdings (cayman) Ltd
Publication of WO2016100349A2 publication Critical patent/WO2016100349A2/en
Publication of WO2016100349A3 publication Critical patent/WO2016100349A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are chemical entities of Formula (I): wherein R1 and Z are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).
PCT/US2015/065829 2014-12-16 2015-12-15 Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists Ceased WO2016100349A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462092791P 2014-12-16 2014-12-16
US62/092,791 2014-12-16

Publications (2)

Publication Number Publication Date
WO2016100349A2 WO2016100349A2 (en) 2016-06-23
WO2016100349A3 true WO2016100349A3 (en) 2016-08-18

Family

ID=56127835

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/065829 Ceased WO2016100349A2 (en) 2014-12-16 2015-12-15 Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists

Country Status (1)

Country Link
WO (1) WO2016100349A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9567341B2 (en) 2014-09-15 2017-02-14 Rugen Holdings (Cayman) Limited Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists
EP3253761A4 (en) 2015-02-04 2018-06-20 Rugen Holdings (Cayman) Limited 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists
KR102613179B1 (en) 2015-06-01 2023-12-14 뤼겐 홀딩스 (케이맨) 리미티드 3,3-Difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists
EP3544610A1 (en) 2016-11-22 2019-10-02 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
JP7318015B2 (en) 2019-06-04 2023-07-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Purine derivatives as NR2B negative modulators and their use as medicaments, in particular for the treatment of depressive disorders
WO2020245137A1 (en) 2019-06-04 2020-12-10 Boehringer Ingelheim International Gmbh Imidazopyrazine derivatives and the use thereof as medicament
CN114213424B (en) * 2021-12-30 2023-05-26 杭州高光制药有限公司 Synthesis method of furan [3,2-b ] pyridine derivative

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020165241A1 (en) * 2001-02-23 2002-11-07 Claiborne Christopher F. N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
US20030018038A1 (en) * 1999-10-29 2003-01-23 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US20070149568A1 (en) * 2003-06-04 2007-06-28 Liverton Nigel J N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
US20110172415A1 (en) * 2006-02-23 2011-07-14 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030018038A1 (en) * 1999-10-29 2003-01-23 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US20020165241A1 (en) * 2001-02-23 2002-11-07 Claiborne Christopher F. N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
US20070149568A1 (en) * 2003-06-04 2007-06-28 Liverton Nigel J N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
US20110172415A1 (en) * 2006-02-23 2011-07-14 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group

Also Published As

Publication number Publication date
WO2016100349A2 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
WO2016100349A3 (en) Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists
TN2017000524A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
WO2015118342A8 (en) Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists
NZ737399A (en) Ccr2 modulators
TN2016000263A1 (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
MX2017002775A (en) Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists.
MX2021002978A (en) Bicyclic lactams and methods of use thereof.
MX379110B (en) AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS.
MY193728A (en) Muscarinic receptor agonists
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
TN2018000395A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
EA033497B1 (en) 1-(thiophenyl or phenyl)sulfonyl(pyrrolidine)-2-carboxamide derivatives and use thereofas trpa1 antagonists
TN2018000410A1 (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
MX380424B (en) HETEROCYCLIC 3,3-DIFLUORPIPERIDINE CARBAMATE COMPOUNDS AS ANTAGONISTS OF THE N-METHYL-D-ASPARTATE (NMDA) NR2B RECEPTOR.
TN2017000521A1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
WO2014066799A3 (en) Modulators of resistant androgen receptor
AR100733A1 (en) DERIVATIVES OF DIFLUOROETHYLIPIRIDINE AS ANTAGONISTS OF THE NMDA NR2B RECEIVER
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
WO2014159794A3 (en) Bicyclo [2.2.1] acid gpr120 modulators
PH12016501483A1 (en) P-substituted asymmetric ureas and medical uses thereof
PH12016501625A1 (en) Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists
WO2015111004A3 (en) Improved process for the preparation of chlorophenyl trifluoroethanone
EP3227306A4 (en) Process for the preparation of tert-butyl 4-((2s,5r)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate and analogs thereof
HK1219723A1 (en) Piperidine and azepine derivatives as prokineticin receptor modulators
MX2017015300A (en) Aminoester derivatives.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15870879

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15870879

Country of ref document: EP

Kind code of ref document: A2